# Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

> **NCT01673438** · PHASE1 · COMPLETED · sponsor: **ImmunityBio, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** aldoxorubicin

## Key facts

- **NCT ID:** NCT01673438
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01673438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01673438, "Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01673438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*